GABA B receptors in addiction and its treatment

Advances in Pharmacology

Volumn 58, Issue C, 2010, Pages 373-396

  Tyacke, Robin J ^a   Lingford Hughes, Anne ^a   Reed, Laurence J ^a   Nutt, David J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Addiction; Baclofen; Craving; Human; Tiagabine; Vigabatrin

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; 4 HYDROXYBUTYRIC ACID; BACLOFEN; CLONIDINE; DIAZEPAM; DONEPEZIL; GABAPENTIN; METHAMPHETAMINE; PLACEBO; SERTRALINE; TIAGABINE; VIGABATRIN; STREET DRUG;

ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE THERAPY; COUNSELING; DIZZINESS; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; HEADACHE; HUMAN; HYPOTENSION; MOTIVATION; MUSCLE WEAKNESS; NAUSEA; OPIATE ADDICTION; PRIORITY JOURNAL; SOMNOLENCE; TOBACCO DEPENDENCE; VISUAL FIELD DEFECT; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA; ADDICTION; ANIMAL; METABOLISM; REVIEW;

ALCOHOLISM; ANIMALS; HUMANS; RECEPTORS, GABA-B; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 77955074281     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(10)58014-1     Document Type: Chapter

References (63)

1. Abdelkader H., Youssef Abdalla O., Salem H. Formulation of controlled-release baclofen matrix tablets. II. Influence of some hydrophobic excipients on the release rate and in vitro evaluation. AAPS PharmSciTech 2008, 9(2):675-683.
2. Addolorato G., Caputo F., Capristo E., et al. A case of gamma-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: Utility of diazepam administration. Clinical Neuropharmacology 1999, 22(1):60-62.
3. Addolorato G., Caputo F., Capristo E., et al. Ability of baclofen in reducing alcohol craving and intake: II-Preliminary clinical evidence. Alcoholism, Clinical and Experimental Research 2000, 24(1):67-71.
4. Addolorato G., Caputo F., Capristo E., et al. Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study. Alcohol and Alcoholism 2002, 37(5):504-508.
5. Addolorato G., Caputo F., Capristo E., et al. Rapid suppression of alcohol withdrawal syndrome by baclofen. American Journal of Medicine 2002, 112(3):226-229.
6. Addolorato G., Leggio L., Abenavoli L., et al. Suppression of alcohol delirium tremens by baclofen administration: A case report. Clinical Neuropharmacology 2003, 26(5):258-262.
7. Addolorato G., Leggio L., Abenavoli L., et al. Baclofen in the treatment of alcohol withdrawal syndrome: A comparative study vs diazepam. American Journal of Medicine 2006, 119(3):276. e213-e278.
8. Addolorato G., Leggio L., Ferrulli A., et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study. Lancet 2007, 370(9603):1915-1922.
9. Agabio R., Marras P., Addolorato G., et al. Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: A case report. Journal of Clinical Psychopharmacology 2007, 27(3):319-320.
10. Ahmadi-Abhari S.A., Akhondzadeh S., Assadi S.M., et al. Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: A double-blind randomized controlled trial. Journal of Clinical Pharmacy and Therapeutics 2001, 26(1):67-71.
11. Akhondzadeh S., Ahmadi-Abhari S.A., Assadi S.M., et al. Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal. Journal of Clinical Pharmacy and Therapeutics 2000, 25(5):347-353.
12. B receptor in the nucleus accumbens and the medial prefrontal cortex of the rat after chronic treatment with nicotine. Neuroscience Letters 2004, 355(3):161-164.
13. Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: A self-case report of a physician. Alcohol and Alcoholism 2005, 40(2):147-150.
14. Assadi S.M., Radgoodarzi R., Ahmadi-Abhari S.A. Baclofen for maintenance treatment of opioid dependence: A randomized double-blind placebo-controlled clinical trial [ISRCTN32121581]. BMC Psychiatry 2003, 3:16.
15. Brebner K., Childress A.R., Roberts D.C. A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. Alcohol and Alcoholism 2002, 37(5):478-484.
16. Brodie J.D., Case B.G., Figueroa E., et al. Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. American Journal of Psychiatry 2009, 166(11):1269-1277.
17. Brodie J.D., Figueroa E., Dewey S.L. Treating cocaine addiction: From preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 2003, 50(3):261-265.
18. Brodie J.D., Figueroa E., Laska E.M., et al. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005, 55(2):122-125.
19. Bucknam W. Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol and Alcoholism 2007, 42(2):158-160.
20. Caputo F., Vignoli T., Maremmani I., et al. Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: A review. International Journal of Environmental Research and Public Health 2009, 6(6):1917-1929.
21. B receptor in limbic areas of alcohol-preferring and -nonpreferring rats. European Journal of Pharmacology 2005, 523(1-3):67-70.
22. Cousins M.S., Stamat H.M., de Wit H. Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking. Nicotine & Tobacco Research 2001, 3(2):123-129.
23. Craig K., Gomez H.F., McManus J.L., et al. Severe gamma-hydroxybutyrate withdrawal: A case report and literature review. Journal of Emergency Medicine 2000, 18(1):65-70.
24. Cryan J.F., Kaupmann K. Don't worry 'b' happy!: A role for GABA(B) receptors in anxiety and depression. Trends in Pharmacological Sciences 2005, 26(1):36-43.
25. De La Garza R., Zorick T., Heinzerling K.G., et al. The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers. Pharmacology Biochemistry and Behavior 2009, 94(1):186-193.
26. Dewey S.L., Chaurasia C.S., Chen C.E., et al. GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse 1997, 25(4):393-398.
27. Dewey S.L., Morgan A.E., Ashby C.R., et al. A novel strategy for the treatment of cocaine addiction. Synapse 1998, 30(2):119-129.
28. Evans S.M., Bisaga A. Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcoholism, Clinical and Experimental Research 2009, 33(1):19-30.
29. Fechtner R.D., Khouri A.S., Figueroa E., et al. Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: Ocular safety pilot results. Archives of Ophthalmology 2006, 124(9):1257-1262.
30. Fink-Jensen A., Suzdak P.D., Swedberg M.D., et al. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. European Journal of Pharmacology 1992, 220(2-3):197-201.
31. Flannery B.A., Garbutt J.C., Cody M.W., et al. Baclofen for alcohol dependence: A preliminary open-label study. Alcoholism, Clinical and Experimental Research 2004, 28(10):1517-1523.
32. Franklin T.R., Harper D., Kampman K., et al. The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug and Alcohol Dependence 2009, 103(1-2):30-36.
33. Garbutt J.C. The state of pharmacotherapy for the treatment of alcohol dependence. Journal of Substance Abuse Treatment 2009, 36(1):S15-S23.
34. Gonzalez G., Desai R., Sofuoglu M., et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug and Alcohol Dependence 2007, 87(1):1-9.
35. Gonzalez G., Sevarino K., Sofuoglu M., et al. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: Results of a randomized pilot study. Addiction 2003, 98(11):1625-1632.
36. Haney M., Hart C.L., Foltin R.W. Effects of baclofen on cocaine self-administration: Opioid- and nonopioid-dependent volunteers. Neuropsychopharmacology 2006, 31(8):1814-1821.
37. Heinzerling K.G., Shoptaw S., Peck J.A., et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug and Alcohol Dependence 2006, 85(3):177-184.
38. Hilton E.J., Hosking S.L., Betts T. The effect of antiepileptic drugs on visual performance. Seizure 2004, 13(2):113-128.
39. Kahn R., Biswas K., Childress A.R., et al. Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. Drug and Alcohol Dependence 2009, 103(1-2):59-64.
40. Kato K., Zhang M.R., Suzuki K. Synthesis of (R,S)-[4-11c]baclofen via Michael addition of nitromethane labeled with short-lived 11c. Bioorganic & Medicinal Chemistry Letters 2009, 19(21):6222-6224.
41. Krystal J.H., McDougle C.J., Kosten T.R., et al. Baclofen-assisted detoxification from opiates. A pilot study. Journal of Substance Abuse Treatment 1992, 9(2):139-142.
42. Kushner S.A., Dewey S.L., Kornetsky C. The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. Journal of Pharmacology and Experimental Therapeutics 1999, 290(2):797-802.
43. Lagarce F., Faisant N., Desfontis J.C., et al. Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: In vitro and in vivo evaluation. European Journal of Pharmaceutics and Biopharmaceutics 2005, 61(3):171-180.
44. Leone M.A., Vigna-Taglianti F., Avanzi G., et al. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database of Systematic Reviews 2010, 2. CD006266.
45. LeTourneau J.L., Hagg D.S., Smith S.M. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocritical Care 2008, 8(3):430-433.
46. Li S.P., Park M.S., Kim J.H., et al. Chronic nicotine and smoke treatment modulate dopaminergic activities in ventral tegmental area and nucleus accumbens and the gamma-aminobutyric acid type B receptor expression of the rat prefrontal cortex. Journal of Neuroscience Research 2004, 78(6):868-879.
47. Lile J.A., Stoops W.W., Allen T.S., et al. Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans. Psychopharmacology (Berl) 2004, 171(4):441-449.
48. Lile J.A., Stoops W.W., Glaser P.E., et al. Acute administration of the GABA reuptake inhibitor tiagabine does not alter the effects of oral cocaine in humans. Drug and Alcohol Dependence 2004, 76(1):81-91.
49. Ling W., Shoptaw S., Majewska D. Baclofen as a cocaine anti-craving medication: A preliminary clinical study. Neuropsychopharmacology 1998, 18(5):403-404.
50. Lingenhoehl K., Brom R., Heid J., et al. Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors. Neuropharmacology 1999, 38(11):1667-1673.
51. Lingford-Hughes A.R., Welch S., Nutt D.J. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 2004, 18(3):293-335.
52. Miotto K., Darakjian J., Basch J., et al. Gamma-hydroxybutyric acid: Patterns of use, effects and withdrawal. American Journal on Addictions 2001, 10(3):232-241.
53. Myrick H., Taylor B., LaRowe S., et al. A retrospective chart review comparing tiagabine and benzodiazepines for the treatment of alcohol withdrawal. Journal of Psychoactive Drugs 2005, 37(4):409-414.
54. Peris J., Eppler B., Hu M., et al. Effects of chronic ethanol exposure on GABA receptors and GABAB receptor modulation of 3h-GABA release in the hippocampus. Alcoholism, Clinical and Experimental Research 1997, 21(6):1047-1052.
55. Shoptaw S., Yang X., Rotheram-Fuller E.J., et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: Preliminary effects for individuals with chronic patterns of cocaine use. Journal of Clinical Psychiatry 2003, 64(12):1440-1448.
56. Sofuoglu M., Mouratidis M., Yoo S., et al. Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) 2005, 181(3):504-510.
57. Sofuoglu M., Poling J., Mitchell E., et al. Tiagabine affects the subjective responses to cocaine in humans. Pharmacology Biochemistry and Behavior 2005, 82(3):569-573.
58. Stuppaeck C.H., Deisenhammer E.A., Kurz M., et al. The irreversible gamma-aminobutyrate transaminase inhibitor vigabatrin in the treatment of the alcohol withdrawal syndrome. Alcohol and Alcoholism 1996, 31(1):109-111.
59. van Noorden M.S., van Dongen L.C., Zitman F.G., et al. Gamma-hydroxybutyrate withdrawal syndrome: Dangerous but not well-known. General Hospital Psychiatry 2009, 31(4):394-396.
60. Winhusen T., Somoza E., Ciraulo D.A., et al. A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence. Drug and Alcohol Dependence 2007, 91(2-3):141-148.
61. Winhusen T.M., Somoza E.C., Harrer J.M., et al. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 2005, 100(Suppl. 1):68-77.
62. Wojtowicz J.M., Yarema M.C., Wax P.M. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: A case report and systematic review. Canadian Journal of Emergency Medical Care 2008, 10(1):69-74.
63. Wong C.G., Bottiglieri T., Snead O.C. GABA, gamma-hydroxybutyric acid, and neurological disease. Annals of Neurology 2003, 54(Suppl. 6):S3-S12.